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Alkaptonuria (AKU) is an orphan inherited homogentisate
dioxygenase enzyme deficiency resulting in accumulation
of homogentisic acid (HGA). HGA is converted to a black
pigment polymer known as ochronosis that causes tissue
damage affecting many tissues including joints and heart,
with significant poor quality of life. The DevelopAKUre
project is a Europe-wide collaboration to study the efficacy
and safety of nitisinone as a potential treatment in three
clinical studies. The first is a phase 2 dose-response study
(SONIA 1) which will determine the optimal dose of niti-
sinone that decreases HGA levels. The second is a phase
III efficacy study (SONIA 2) based on the optimal dose
and the third is a cross-sectional study (SOFIA) that will
define the age that treatment should begin after determin-
ing the onset of ochronosis. Details and rationale of the
SONIA 2 design will be described, with special attention
to issues arising from the rarity of the disease.
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